title: [Therapeutic strategy for prostate specific antigen (PSA) failure after radical prostatectomy].
abstract: Prostate specific antigen (PSA) failure occurs in 20% to 50% of patients who undergo radical prostatectomy. There is no consensus on how PSA failure should be managed. Recently, salvage radiotherapy is reported to be an effective treatment for PSA failure, and 20%-70% of cases are recurrence-free. The aim of salvage radiotherapy is a cure and this is quite different from other options, for example, endocrine therapy. Salvage radiotherapy is likely to become more important as a treatment for PSA failure after radical prostatectomy.
authors.affiliation: Department of Urology, Kyoto University Graduate School of Medicine, 54 Shogoin-kawaramachi, Sakyo-ku, Kyoto 606-8507, Japan.
authors.forename: Hidefumi
authors.initials: H
authors.lastname: Kinoshita
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kamoto
authors.forename: Michihide
authors.initials: M
authors.lastname: Mitsumori
authors.forename: Takehiko
authors.initials: T
authors.lastname: Kiyokawa
authors.forename: Tomonori
authors.initials: T
authors.lastname: Habuchi
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Kakehi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Hiraoka
authors.forename: Osamu
authors.initials: O
authors.lastname: Ogawa
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D008297:Male; D011182:Postoperative Care; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000532:radiotherapy* / Q000601:surgery; D016879:Salvage Therapy
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen